Tamoxifen, which is a selective ER modulator and has an inhibitory effect on estrogen-dependent transcription in breast cancer, inhibits recruitment of NCOA1-3 and induces recruitment of NCOR1 and NCOR2 [18,20,21,22]. This evidence concerns the gene ESR1 and breast carcinoma.